INBX · Inhibrx Biosciences, Inc.
The AI's read
The response rate compares with 15% to 30% for irinotecan and temozolomide alone. Median time before disease worsened was 6.0 months, versus 3 to 4 months with those drugs alone. Responses lasted more than 6 months in 18 patients, and the company reported no unexpected liver injury. Still, ozekibart is being tested for Ewing sarcoma, so these results do not establish approval or benefit for every patient.